These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37414632)

  • 1. [Dysimmune manifestations associated with myelodysplastic neoplasms and chronic myelomonocytic leukaemias].
    Jachiet V; Hadjadj J; Zhao LP; Chasset F; Fain O; Fenaux P; Mekinian A
    Bull Cancer; 2023 Nov; 110(11):1147-1155. PubMed ID: 37414632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study.
    Mekinian A; Grignano E; Braun T; Decaux O; Liozon E; Costedoat-Chalumeau N; Kahn JE; Hamidou M; Park S; Puéchal X; Toussirot E; Falgarone G; Launay D; Morel N; Trouiller S; Mathian A; Gombert B; Schoindre Y; Lioger B; De Wazieres B; Amoura Z; Buchdaul AL; Georgin-Lavialle S; Dion J; Madaule S; Raffray L; Cathebras P; Piette JC; Rose C; Ziza JM; Lortholary O; Montestruc F; Omouri M; Denis G; Rossignol J; Nimubona S; Adès L; Gardin C; Fenaux P; Fain O
    Rheumatology (Oxford); 2016 Feb; 55(2):291-300. PubMed ID: 26350487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Polymyalgia rheumatic and chronic myelomonocytic leukemia].
    Delapierre A; Nganoa C; Maitre E; Briet-Rochoux Q; Maillot F; Aouba A; Audemard-Verger A
    Rev Med Interne; 2021 Jun; 42(6):434-437. PubMed ID: 33129580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.
    Mekinian A; Zhao LP; Chevret S; Desseaux K; Pascal L; Comont T; Maria A; Peterlin P; Terriou L; D'Aveni Piney M; Gourin MP; Vey N; Rauzy OB; Grobost V; Bezanahary H; Dimicoli-Salazar S; Banos A; Wickenhauser S; De Renzis B; Durot E; Natarajan-Amé S; Voillat L; Chermat F; Lemaire K; Jachiet V; Himberlin C; Thépot S; Diaz JMT; Frenzel L; Gyan E; Denis G; Hirsch P; Kosmider O; Ades L; Fain O; Fenaux P
    Leukemia; 2022 Nov; 36(11):2739-2742. PubMed ID: 36104395
    [No Abstract]   [Full Text] [Related]  

  • 5. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
    Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
    Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome.
    Kataoka A; Mizumoto C; Kanda J; Iwasaki M; Sakurada M; Oka T; Fujimoto M; Yamamoto Y; Yamashita K; Nannya Y; Ogawa S; Takaori-Kondo A
    Int J Hematol; 2023 Jun; 117(6):919-924. PubMed ID: 36641501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study.
    Péan de Ponfilly-Sotier M; Jachiet V; Benhamou Y; Lahuna C; De Renzis B; Kottler D; Voillat L; Dimicoli-Salazar S; Banos A; Chauveheid MP; Alexandra JF; Grignano E; Liferman F; Laborde M; Broner J; Michel M; Lambotte O; Laribi K; Venon MD; Dussol B; Martis N; Thepot S; Park S; Couret D; Roux-Sauvat M; Terriou L; Hachulla E; Bally C; Galland J; Allain JS; Parcelier A; Peterlin P; Cohen-Bittan J; Regent A; Ackermann F; Le Guen J; Algrin C; Charles P; Daguindau E; Puechal X; Dunogue B; Blanchard-Delaunay C; Beyne-Rauzy O; Grobost V; Schmidt J; Le Gallou T; Dubos-Lascu G; Sonet A; Denis G; Roy-Peaud F; Fenaux P; Adès L; Fain O; Mekinian A;
    Clin Exp Rheumatol; 2022 Jul; 40(7):1336-1342. PubMed ID: 35579092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases.
    Jachiet V; Ricard L; Hirsch P; Malard F; Pascal L; Beyne-Rauzy O; Peterlin P; Maria ATJ; Vey N; D'Aveni M; Gourin MP; Dimicoli-Salazar S; Banos A; Wickenhauser S; Terriou L; De Renzis B; Durot E; Natarajan-Ame S; Vekhoff A; Voillat L; Park S; Vinit J; Dieval C; Dellal A; Grobost V; Willems L; Rossignol J; Solary E; Kosmider O; Dulphy N; Zhao LP; Adès L; Fenaux P; Fain O; Mohty M; Gaugler B; Mekinian A;
    Clin Exp Med; 2023 Jul; 23(3):803-813. PubMed ID: 35953763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid Clonal Infiltrate Identified With Next-Generation Sequencing in Skin Lesions Associated With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case Series.
    Martin de Frémont G; Hirsch P; Gimenez de Mestral S; Moguelet P; Ditchi Y; Emile JF; Senet P; Georgin-Lavialle S; Hanslik T; Maurier F; Adedjouma A; Abisror N; Mahevas T; Malard F; Adès L; Fenaux P; Fain O; Chasset F; Mekinian A
    Front Immunol; 2021; 12():715053. PubMed ID: 34671345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study.
    Roupie AL; Guedon A; Terrier B; Lahuna C; Jachiet V; Regent A; de Boysson H; Carrat F; Seguier J; Terriou L; Versini M; Queyrel V; Groh M; Benhamou Y; Maurier F; Ledoult E; Clech LL; D'Aveni M; Rossignol J; Galland J; Willems L; Chiche NJ; Peterlin P; Roux-Sauvat M; Parcelier A; Wemeau M; Lambert M; Belizna C; Puechal X; Swiader L; Cohen-Valensi R; Noc V; Dao E; Thepot S; de Frémont GM; Tanguy-Schmidt A; Koka AM; Bussone G; Philipponnet C; Konate A; Cavaille G; Guilpain P; Allain JS; Broner J; Solary E; Ruivard M; de Renzis B; Corm S; Baati N; Schleinitz N; Ponsoye M; Stamatoullas-Bastard A; Ades L; Dellal A; Tchirkov A; Aouba A; Fenaux P; Fain O; Mekinian A;
    Semin Arthritis Rheum; 2020 Oct; 50(5):879-884. PubMed ID: 32896704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Wei Y; Zheng H; Lockyer PP; Darbaniyan F; Li Z; Kanagal-Shamanna R; Soltysiak KA; Yang H; Ganan-Gomez I; Montalban-Bravo G; Chien KS; Do KA; Daver N; Garcia-Manero G
    Leuk Lymphoma; 2022 Dec; 63(13):3154-3164. PubMed ID: 36059252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
    Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
    Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review and meta
    Kunacheewa C; Thongthang P; Ungprasert P; Utchariyaprasit E; Owattanapanich W
    Hematology; 2019 Dec; 24(1):498-506. PubMed ID: 31221030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Skin manifestations associated with myelodysplastic syndromes].
    Morand JJ; Lightburn E; Richard MA; Hesse-Bonerandi S; Carsuzaa F; Grob JJ
    Rev Med Interne; 2001 Sep; 22(9):845-53. PubMed ID: 11599186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Jachiet V; Moulis G; Hadjadj J; Seguier J; Laribi K; Schleinitz N; Vey N; Sacre K; Godeau B; Beyne-Rauzy O; Bouvet R; Broner J; Brun N; Comont T; Gaudin C; Lambotte O; Le Clech L; Peterlin P; Roy-Peaud F; Salvado C; Versini M; Isnard F; Kahn JE; Gobert D; Adès L; Fenaux P; Fain O; Mekinian A
    Haematologica; 2021 May; 106(5):1414-1422. PubMed ID: 33626866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.
    Mądry K; Lis K; Biecek P; Młynarczyk M; Rytel J; Górka M; Kacprzyk P; Dutka M; Rodzaj M; Bołkun Ł; Krochmalczyk D; Łątka E; Drozd-Sokołowska J; Waszczuk-Gajda A; Knopińska-Posłuszny W; Kopińska A; Subocz E; Masternak A; Guzicka-Kazimierczak R; Gil L; Machowicz R; Biliński J; Giebel S; Czerw T; Dwilewicz-Trojaczek J
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):264-274.e4. PubMed ID: 30898482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.
    Triguero A; Xicoy B; Zamora L; Jiménez MJ; García O; Calabuig M; Díaz-Beyá M; Arzuaga J; Ramos F; Medina A; Bernal T; Talarn C; Coll R; Collado R; Chen TH; Borrás J; Brunet S; Marchante I; Marco V; López-Cadenas F; Calbacho M; Simiele A; Cortés M; Cedena MT; Pedreño M; Aguilar C; Pedró C; Fernández M; Stoica C; Ribera JM; Sanz G
    Leuk Res; 2022 May; 116():106836. PubMed ID: 35405632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
    van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
    Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased cardiovascular comorbidities in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia presenting with systemic inflammatory and autoimmune manifestations.
    Kipfer B; Daikeler T; Kuchen S; Hallal M; Andina N; Allam R; Bonadies N
    Semin Hematol; 2018 Oct; 55(4):242-247. PubMed ID: 30502853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.